ICON to acquire Clinical Research Management Inc.

Acquisition extends ICON’s presence in the market for government sponsored research and enhances capabilities in Vaccines and Infectious Disease

Dublin, Ireland, 30^th June 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced it has agreed, subject to certain customary closing conditions (including applicable regulatory approvals), to acquire Clinical Research Management Inc. (ClinicalRM). The acquisition will enhance ICON’s ability to access the market for government sponsored research and further enhances ICON’s capabilities in the areas of Vaccines and Infectious Disease.

Read More

ICON Announces Service Agreement with Pfizer

DUBLIN–(BUSINESS WIRE)– ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE:PFE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.

The new agreement builds on the companies’ existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.

Ciaran Murray, ICON’s CEO, commented:  “The progression of our relationship with Pfizer is a recognition of ICON’s capabilities in supporting drug development efforts. We look forward to continuing our relationship with Pfizer to help advance its development pipeline and innovation in the drug development process.”

Read More

ICON-sponsored research by Carnegie Mellon University validates shorter and simpler patient consent processes in clinical trials

Opportunities to reduce content on consent forms by over 80% and using video formats can improve patient comprehension and engagement 

Dublin, Ireland, 7^th June – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today welcomed the results of ICON-supported research at Carnegie Mellon University (CMU) which validate  a shorter, simple approach to patient consent processes.

The results, which were recently published in Medical Decision Making journal, show that patient consent forms could be shortened by up to 86% without losing critical understanding or sacrificing the content required by ethics boards. The research also found greater patient engagement when using a shorter paper form or when using a video format, compared with more traditional, paper-based approaches.

Read More

Almac Group Appoints New Vice President of Corporate Marketing

Craigavon, N.I., UK – 2 June 2016 – Almac Group, the global contract development and manufacturing organisation is pleased to announce the appointment of Kevin Reid to the position of Vice President of Corporate Marketing.

Kevin’s role will be to lead Almac’s Global Corporate Marketing team, support each of Almac’s business units in the design, management and implementation of their marketing plans as well as driving the overall Almac Group communications.

Read More